Q-omics provides the consensus-scored PLEKHF1 profile across patient tissues and cancer cell-line models. PLEKHF1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PLEKHF1 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, PLEKHF1 protein abundance shows 21,098 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, and LSCC as cancer lineages where PLEKHF1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLEKHF1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLEKHF1 survival associations across molecular data types. PLEKHF1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLEKHF1 RNA expression–survival associations across cancer types. High PLEKHF1 expression shows unfavorable associations in KIRC, LUSC, OV and LGG, but favorable associations in BLCA and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PLEKHF1 RNA expression.
This table summarizes PLEKHF1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PLEKHF1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLEKHF1 shows lower tumor expression in BRCA and PRAD and higher tumor expression in KIRC, KIRP, LIHC and KICH. The KIRC box plot shows higher PLEKHF1 RNA expression in tumor versus normal tissue (log2 FC = +1.167, t-test p < 0.001).
This table shows molecular features associated with PLEKHF1 in patient tissues and cancer cell lines. In patient samples, PLEKHF1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PLEKHF1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BONE.
